Total biosynthesis of the cyclic AMP booster forskolin from Coleus forskohlii

  1. Irini Pateraki  Is a corresponding author
  2. Johan Andersen-Ranberg
  3. Niels Bjerg Jensen
  4. Sileshi Gizachew Wubshet
  5. Allison Maree Heskes
  6. Victor Forman
  7. Björn Hallström
  8. Britta Hamberger
  9. Mohammed Saddik Motawia
  10. Carl Erik Olsen
  11. Dan Staerk
  12. Jørgen Hansen
  13. Birger Lindberg Møller
  14. Bjoern Hamberger
  1. University of Copenhagen, Denmark
  2. University of California, Berkeley, United States
  3. Evolva, Denmark
  4. Nofima, Norway
  5. KTH - Royal Institute of Technology, Sweden
  6. Michigan State University, United States

Abstract

Forskolin is a unique structurally complex labdane type diterpenoid used in the treatment of glaucoma and heart failure based on its activity as a cyclic AMP booster. Commercial production of forskolin relies exclusively on extraction from its only known natural source, the plant Coleus forskohlii, in which forskolin accumulates in the root cork. Here we report the discovery of five cytochrome P450s and two acetyltransferases which catalyze a cascade of reactions converting the forskolin precursor 13R-manoyl oxide into forskolin and a diverse array of additional labdane-type diterpenoids. A minimal set of three P450s in combination with a single acetyl transferase was identified that catalyzes the conversion of 13R-manoyl oxide into forskolin as demonstrated by transient expression in Nicotiana benthamiana. The entire pathway for forskolin production from glucose encompassing expression of nine genes was stably integrated into Saccharomyces cerevisiae and afforded forskolin titers of 40 mg/L.

Article and author information

Author details

  1. Irini Pateraki

    Plant Biochemistry Laboratory, Department of Plant and Environmental Sciences, University of Copenhagen, Copenhagen, Denmark
    For correspondence
    eipa@plen.ku.dk
    Competing interests
    Irini Pateraki, Filed international patent600 applications (PCT/DK2015/050020) covering 'Biosynthesis of forskolin and related compounds.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7526-2334
  2. Johan Andersen-Ranberg

    Department of Plant and Microbial Biology, University of California, Berkeley, Berkeley, United States
    Competing interests
    Johan Andersen-Ranberg, Filed international patent600 applications (PCT/DK2015/050020) covering 'Biosynthesis of forskolin and related compounds.
  3. Niels Bjerg Jensen

    Evolva, Copenhagen, Denmark
    Competing interests
    Niels Bjerg Jensen, Filed international patent600 applications (PCT/DK2015/050020) covering 'Biosynthesis of forskolin and related compoundsEmployee of Evolva SA.
  4. Sileshi Gizachew Wubshet

    Nofima, Osloveien, Norway
    Competing interests
    No competing interests declared.
  5. Allison Maree Heskes

    Plant Biochemistry Laboratory, Department of Plant and Environmental Sciences, University of Copenhagen, Copenhagen, Denmark
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2732-5185
  6. Victor Forman

    Plant Biochemistry Laboratory, Department of Plant and Environmental Sciences, University of Copenhagen, Copenhagen, Denmark
    Competing interests
    No competing interests declared.
  7. Björn Hallström

    Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, Sweden
    Competing interests
    No competing interests declared.
  8. Britta Hamberger

    Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, United States
    Competing interests
    No competing interests declared.
  9. Mohammed Saddik Motawia

    Plant Biochemistry Laboratory, Department of Plant and Environmental Sciences, University of Copenhagen, Copenhagen, Denmark
    Competing interests
    No competing interests declared.
  10. Carl Erik Olsen

    Plant Biochemistry Laboratory, Department of Plant and Environmental Sciences, University of Copenhagen, Copenhagen, Denmark
    Competing interests
    No competing interests declared.
  11. Dan Staerk

    Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark
    Competing interests
    No competing interests declared.
  12. Jørgen Hansen

    Evolva, Copenhagen, Denmark
    Competing interests
    Jørgen Hansen, Employee of Evolva SA.
  13. Birger Lindberg Møller

    Plant Biochemistry Laboratory, Department of Plant and Environmental Sciences, University of Copenhagen, Copenhagen, Denmark
    Competing interests
    Birger Lindberg Møller, Filed international patent600 applications (PCT/DK2015/050020) covering 'Biosynthesis of forskolin and related compounds.
  14. Bjoern Hamberger

    Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, United States
    Competing interests
    Bjoern Hamberger, Filed international patent600 applications (PCT/DK2015/050020) covering 'Biosynthesis of forskolin and related compounds'.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1249-1807

Funding

Villum Fonden

  • Birger Lindberg Møller

Novo Nordisk

  • Birger Lindberg Møller

European Commission

  • Irini Pateraki

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2017, Pateraki et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 5,048
    views
  • 799
    downloads
  • 95
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Irini Pateraki
  2. Johan Andersen-Ranberg
  3. Niels Bjerg Jensen
  4. Sileshi Gizachew Wubshet
  5. Allison Maree Heskes
  6. Victor Forman
  7. Björn Hallström
  8. Britta Hamberger
  9. Mohammed Saddik Motawia
  10. Carl Erik Olsen
  11. Dan Staerk
  12. Jørgen Hansen
  13. Birger Lindberg Møller
  14. Bjoern Hamberger
(2017)
Total biosynthesis of the cyclic AMP booster forskolin from Coleus forskohlii
eLife 6:e23001.
https://doi.org/10.7554/eLife.23001

Share this article

https://doi.org/10.7554/eLife.23001

Further reading

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Vikas Navratna, Arvind Kumar ... Shyamal Mosalaganti
    Research Article

    Degradation of heparan sulfate (HS), a glycosaminoglycan (GAG) comprised of repeating units of N-acetylglucosamine and glucuronic acid, begins in the cytosol and is completed in the lysosomes. Acetylation of the terminal non-reducing amino group of α-D-glucosamine of HS is essential for its complete breakdown into monosaccharides and free sulfate. Heparan-α-glucosaminide N-acetyltransferase (HGSNAT), a resident of the lysosomal membrane, catalyzes this essential acetylation reaction by accepting and transferring the acetyl group from cytosolic acetyl-CoA to terminal α-D-glucosamine of HS in the lysosomal lumen. Mutation-induced dysfunction in HGSNAT causes abnormal accumulation of HS within the lysosomes and leads to an autosomal recessive neurodegenerative lysosomal storage disorder called mucopolysaccharidosis IIIC (MPS IIIC). There are no approved drugs or treatment strategies to cure or manage the symptoms of, MPS IIIC. Here, we use cryo-electron microscopy (cryo-EM) to determine a high-resolution structure of the HGSNAT-acetyl-CoA complex, the first step in the HGSNAT-catalyzed acetyltransferase reaction. In addition, we map the known MPS IIIC mutations onto the structure and elucidate the molecular basis for mutation-induced HGSNAT dysfunction.

    1. Biochemistry and Chemical Biology
    Swarang Sachin Pundlik, Alok Barik ... Arvind Ramanathan
    Short Report

    Senescent cells are characterized by multiple features such as increased expression of senescence-associated β-galactosidase activity (SA β-gal) and cell cycle inhibitors such as p21 or p16. They accumulate with tissue damage and dysregulate tissue homeostasis. In the context of skeletal muscle, it is known that agents used for chemotherapy such as Doxorubicin (Doxo) cause buildup of senescent cells, leading to the inhibition of tissue regeneration. Senescent cells influence the neighboring cells via numerous secreted factors which form the senescence-associated secreted phenotype (SASP). Lipids are emerging as a key component of SASP that can control tissue homeostasis. Arachidonic acid-derived lipids have been shown to accumulate within senescent cells, specifically 15d-PGJ2, which is an electrophilic lipid produced by the non-enzymatic dehydration of the prostaglandin PGD2. This study shows that 15d-PGJ2 is also released by Doxo-induced senescent cells as an SASP factor. Treatment of skeletal muscle myoblasts with the conditioned medium from these senescent cells inhibits myoblast fusion during differentiation. Inhibition of L-PTGDS, the enzyme that synthesizes PGD2, diminishes the release of 15d-PGJ2 by senescent cells and restores muscle differentiation. We further show that this lipid post-translationally modifies Cys184 of HRas in C2C12 mouse skeletal myoblasts, causing a reduction in the localization of HRas to the Golgi, increased HRas binding to Ras Binding Domain (RBD) of RAF Kinase (RAF-RBD), and activation of cellular Mitogen Activated Protein (MAP) kinase–Extracellular Signal Regulated Kinase (Erk) signaling (but not the Akt signaling). Mutating C184 of HRas prevents the ability of 15d-PGJ2 to inhibit the differentiation of muscle cells and control the activity of HRas. This work shows that 15d-PGJ2 released from senescent cells could be targeted to restore muscle homeostasis after chemotherapy.